Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor
Fusion vaccine given with IL-12 for patients with breast cancer.
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body
build an effective immune response to kill tumor cells. Interleukin-12 may stimulate the
white blood cells to kill tumor cells. Giving vaccine therapy together with interleukin-12
may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of interleukin-12
when given together with vaccine therapy and to see how well they work in treating women with
stage IV breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard Medical School Harvard Medical School (HMS and HSDM) National Cancer Institute (NCI) United States Department of Defense